Rivastigmine


Generic Medicine Info
Administration
Should be taken with food.
Special Precautions
Patient with sick sinus syndrome, bradycardia, or conduction defects; risk of ulcer disease; respiratory diseases (e.g. COPD, asthma); history of seizure disorder; bladder outlet obstruction, prostatic hyperplasia; body weight <50 kg. Mild to moderate hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may impair physical and mental abilities, if affected, do not drive or operate machinery. Monitoring Parameters Monitor cognitive function periodically; body weight, and symptoms of gastrointestinal intolerance.
Adverse Reactions
Significant: Allergic dermatitis (patch); CNS depression, extrapyramidal symptoms, nausea, vomiting, diarrhoea, anorexia, weight loss, decreased appetite, bradycardia, heart block. Gastrointestinal disorders: Abdominal pain, dyspepsia. General disorders and administration site conditions: Application site erythema, fatigue. Injury, poisoning and procedural complications: Falling. Nervous system disorders: Dizziness, headache, tremor, drowsiness, agitation, seizures. Psychiatric disorders: Insomnia, confusion, depression.
Drug Interactions
Additive effect with succinylcholine-type muscle relaxants during anaesthesia; cholinometric substances (e.g. oxybutynin, tolterodine). Additive effect and increased risk of bradycardia with beta-blockers (e.g. atenolol). Increased risk of torsade de pointes with phenothiazines (e.g. chlorpromazine); benzamides (e.g. sulpiride, sultopride), pimozide, cisapride.
ATC Classification
N06DA03 - rivastigmine ; Belongs to the class of anticholinesterases. Used in the management of dementia.
Disclaimer: This information is independently developed by CIMS based on rivastigmine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in